<a href="https://laohu8.com/S/TWST">Twist Bioscience</a> reports record $376.6 million revenue for fiscal 2025
Twist Bioscience Corporation reported record total revenue of $376.6 million for fiscal year 2025, a 20% increase from $313.0 million in fiscal year 2024. Fourth quarter revenue reached $99.0 million, up 17% from $84.7 million in the same quarter last year, marking the company's 11th consecutive quarter of sequential growth. SynBio revenue for fiscal 2025 was $145.0 million, representing a 17% increase from $123.5 million in fiscal 2024. Gross margin improved to 50.7% in fiscal 2025, up from 42.6% the previous year. The company appointed Trynka Shineman to its board of directors. For fiscal 2026, Twist Bioscience expects total revenue between $425 million and $435 million, with DNA Synthesis and Protein Solutions revenue projected at $194 million to $199 million and NGS Applications revenue at $231 million to $236 million. Gross margin is expected to exceed 52%, and the company anticipates achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001581280-25-000020), on November 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.